| Autor: |
Urescu, Dumitrita, Musteața, Vasile, Robu, Maria, Musteața, Larisa, Natalia, Sporîș, Cebanu, Irina |
| Předmět: |
|
| Zdroj: |
German International Journal of Modern Science / Deutsche Internationale Zeitschrift für Zeitgenössische Wissenschaft; Oct2024, Issue 91, p34-38, 5p |
| Abstrakt: |
Introduction. Non-Hodgkin lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating from B, T or natural killer (NK) lymphocytes. Clinical scoring systems have been developed to better stratify the patients' risk and help select therapeutic strategies. Materials and methods. Clinical and prognostic stratification scores were applied to 99 patients with extranodal aggressive NHL. The diagnosis was confirmed morphologically by tumor biopsy and immunohistochemistry. Results. IPI is an independent prognostic factor for progression-free survival. In addition, it facilitates the investigation of the independent impact of other prognostic biomarkers through adjusted analyses. Calculating International Prognostic Index (IPI), we obtained the following results: IPI 0 - 25% and IPI1 - 23.2% with a low risk and 5-year survival of 73%, IPI2 - 18.1% with low intermediate risk and 5-year survival of 51%, IPI3 - 17.1% with high intermediate risk and 5-year survival of 43%, IPI4 - 12.1% and IPI 5 - 4.5% with high risk and 5-year survival of 26%. Conclusions. Clinical scoring systems allow better risk stratification of patients and selection of appropriate therapeutic strategies. The IPI is a clinical tool developed to help predict the prognosis of patients with aggressive NHL. RIPI is a clinically useful prognostic index that allows guiding treatment planning in patients with DLBCL. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
